Court proceedings initiated for immediate market approval of Brixadi™ in the US
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product.
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product. Buvidal is approved for the treatment of opioid dependence in the EU and Australia.
Read more at Camurus’ website: https://www.camurus.com/pressreleases/
Latest news
2023-05-23
Sandberg Development Graduate Program - A unique start to your career!
Are you a recent engineering graduate eager to learn more and to develop your personal skills?